Halozyme Therapeutics, Inc. (HALO)
Last updated: 2026-10-21 06:31:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Halozyme Therapeutics, Inc. (HALO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $124.33, with a market capitalization of $13.90B and a P/E ratio of 34.13. Over the past 52 weeks, its price has ranged from $61.23 to $125.10. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$13.90B | |
$123.54 | |
$125.10 | |
$2.60 | |
$122.50 | |
1.90M | |
2.27M | |
34.13 | |
$125.10 | |
$61.23 | |
-- | |
-- |
Halozyme Therapeutics, Inc. (HALO) Latest Closing Stock Price
Halozyme Therapeutics, Inc. (HALO) last closed at $122.50 as of 2026-10-20 23:57:00, unchanged from the previous close of $122.50.
During the latest regular trading session, HALO traded between $2.60 and $125.10, with a volume of 1.90M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Halozyme Therapeutics, Inc. (HALO) 7-Day Stock Price Change
Over the past seven days, Halozyme Therapeutics, Inc. (HALO) moved from $111.08 to $124.33, representing a gain of 11.93% ($13.25).
The stock traded between $108.80 and $125.10 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.26 million shares, up versus the previous seven-day period, indicating higher trading activity.
HALO 52-Week Price Position
Position in Range: 98.8%
HALO is currently trading at $124.33, placing it 98.8% of the way from its 52-week low of $61.23 to its 52-week high of $125.10. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Halozyme Therapeutics, Inc. (HALO)?
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Halozyme Therapeutics, Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 423 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Halozyme Therapeutics, Inc. (HALO) Stock on MEXC
Eligible investors can buy real shares of Halozyme Therapeutics, Inc. (HALO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Halozyme Therapeutics, Inc. (HALO) stock price today?
2.Is HALO stock going up or down today?
3.What is HALO pre-market price?
4.What is HALO after-hours price?
5.Is HALO stock trading now?
6.Where does HALO sit relative to its 52-week high and low?
7.What sector is Halozyme Therapeutics, Inc. in?
8.What is Halozyme Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is HALO valued in terms of P/E ratio and EPS?
10.Does Halozyme Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
HALO Stock Calculator
Estimate the value between HALO shares and USD.
HALO Shares to USD
1.00 HALO shares = 124.329 USD
Calculations are estimates based on the latest available price and are for reference only.


